There’s a lot of questions doing the rounds on forums and messages about the approval of Lutathera (PRRT) in USA, Europe and other places. This is not a place just for one particular country, I want a place to review what is happening globally given my following. In many countries, however, I’m dependent on feedback from patients in those countries. Please note this is not intended to be a 100% complete breakdown on everything about PRRT or PRRT centres – it’s a summary. It should be clear from below but please bear that in mind when reading.
Short PRRT Primer
What is PRRT?
For those who are still not sure what it’s all about. This is a non-surgical treatment which is normally administered intravenously. It’s based on the use of somatostatin receptors to attract a ‘radiopeptide’. The radiopeptide is a combination of a somatostatin analogue and a radioactive material. As we already know, somatostatin analogues (i.e. Lanreotide/Octreotide) are a NET cell targeting drug, so when combined radioactivity, it binds with the NET cells and delivers a high dose of targeted radiation to the cancer while preserving healthy tissue. In general, patients tend to receive up to 4 sessions spaced apart by at least 2 months.
PRRT will not work on all NETs and not everyone will suited to this treatment. In general, for this treatment to be more successful, you must have somatostatin receptors in your tumors. Success rates are not 100% – it should not be considered a cure or ‘magic bullet’. However, the results are said to be pretty good. The NETTER-1 trial data which has led to formal approval in Europe, USA and other areas, can be found here.
Understanding the terminology is half the battle in understanding the latest developments. I’ve included Ga-68 PET scans within this section (or in more general terms Somatostatin Receptor PET (SSTR PET)) as the term ‘Theranostics‘ is becoming a commonly used theme. Theranostics is a joining of the words diagnostics and therapy.
LUTATHERA is the radionuclide ‘mix’ for use in Peptide Radio Therapy Treatment (PRRT). You may also see this drug called ‘Lutetium’ or ‘Lu-177 dotatate’, or just ‘Lu-177’ on its own. Yttrium 90 (Y-90) is a radionuclide also used in PRRT.
NETSPOT (USA) or SOMAKIT TOC (Europe) is not PRRT but it is the commercial names for the radiopeptide used in Gallium 68 (Ga-68) PET diagnostic scans.
Together they form a ‘theranostic pair’. Theranostics is apt as together (NETSPOT / SOMAKIT TOC and Lutathera), both target NETs expressing the same somatostatin receptor, with Lutathera intended to kill tumor cells by emitting a different kind of low-energy, short-range radiation than that of the diagnostic version.
Moreover, thanks to the theranostic approach that nuclear medicine allows, Novartis/AAA’s NETSPOT/SomaKit TOC products will be able to determine when Lutathera is the appropriate treatment.
Read more about Theranostics by clicking here.
LATEST HEADLINE – UK
20 July 2018. National Institute for Health Care Excellence (NICE) has recommended Lutetium (177Lu) oxodotreotide, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults. There is a short interim period where until formal publication takes place. Final appraisal determination covers the period 20 July to 3 Aug 2018 but PRRT is now effectively approved in England. CLICK HERE to read the NICE statements
9 July 2018. The Scottish Medicines Consortium (NICE equivalent) has approved lutetium 177Lu (Lutathera) for patients in NHS Scotland. Good news for Scotland once their hospitals have the capability to deliver. Scottish patients would then not need to travel to England for the NHS Scotland funded treatment. Read more here
Hasn’t the therapy has been in use for some time?
Of course, this therapy has been in use in Europe and some other places for some time but to be honest, they have been on a limited scale and never formally approved by national drug agencies. Despite its extensive use, the EU approval in 2017 was actually the very first approval of PRRT anywhere in the world. For example, in UK, it was used for some time for those in need but was removed from routine availability through a ‘slush fund’ formally known as the Cancer Drugs Fund – to cut a long story short, the funding source was cut off, although there are still ways of obtaining the treatment pending formal acceptance by the NHS (certain criteria apply).
In the meantime, I constantly see stories of patients travelling to Switzerland, Germany, Netherlands, Sweden, Great Britain and others; mostly at their own cost. However, it does indicate one thing, there is a huge unmet need in that many patients do not have access to the best treatments in their own country. I see this daily through many private messages.
What about Grade 3 (High Grade) Neoplasms?
The main treatment for Grade 3 is chemotherapy, particularly poorly differentiated. PRRT tends to work better with efficient somatostatin receptors (i.e. somatostatin receptor-positive tumors). The European approval wording only covers Grades 1 and 2. The US FDA approval indicates “somatostatin receptor-positive tumors”. It’s also worth noting that with Grade 3, are more likely to exist in Grade 3 well differentiated NETs, particularly in the lower Ki-67 readings. However, there’s an interesting study from Australia which might be useful to read – check out the abstract here (note the full version is not available free).
What about Pheochromoctyoma/Paraganglioma?
There’s actually still a trial for Pheochromocytoma/Paraganglioma (Pheo/Para). It is known that Pheo/Para can have somatostatin receptor tumors so a useful trial. The aim of the trial is to assess the safety and tolerability. You can read about the trial here.
The aim of this section is to update on a regional basis in order to inform an international community of followers and readers.
This section of this article will cover each region, indicating where PRRT can be obtained (as far as I know). It is not designed to indicate whether this is through public or private facilities (this will depend to too many factors beyond the reach of this article). Please note this is not intended to be a 100% complete breakdown on everything single PRRT centre – it’s a summary. It should be clear from below but please bear that in mind when reading.
On 20th July 2018. National Institute for Health Care Excellence (NICE) has recommended Lutetium (177Lu) oxodotreotide, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults. PRRT is also approved and funded in Scotland. It is funded in Wales and Northern Ireland but is currently administered in England with inter NHS budget transfers.
PRRT was approved in USA on 26 Jan 2018. The approval is for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. CLICK HERE.
The extended access program (trial) is no longer offered but these locations should be ahead of the game in terms of provision, notwithstanding insurance and provision of sufficient nuclear material.
In the meantime, known USA sites offering routine “live site” insurance based PRRT treatment are as follows – please note information has been gleaned from US patients due to no other consolidated source of this information being readily available. It’s possible some patients got mixed up between trial locations and live locations so let me know of any omissions or additions/corrections – thanks in advance.
DRAFT – NOT YET COMPLETE – (as at 28 July 2018)
|STATE||LOCATION||Due in Service?||CONTACT DETAILS|
|Arizona||Banner||Now||Dr Boris Naraev|
|California||UCSF Medical Center||Now||tbc|
|California||Palo Alto VA||Summer 2018||tbc|
|California||Cedars Sinai Medical Center||now||tbc|
|California||Stanford Medical Center||Now||tbc|
|California||Kaiser Permanente Los Angeles Medical Center||Now||tbc|
|California||Hoag Hospital Newport Beach||Now||tbc|
|California||Kaiser Santa Clara Medical Center||Now||tbc|
|California||City of Hope LA||Now||tbc|
|California||Kaiser San Francisco||Summer 2018||tbc|
|California||UC San Diego||Summer 2018||tbc|
|Colorado||Rocky Mountain Cancer Center Denver||Now||Dr Eric Liu|
|Colorado||University of Colorado UC Health Denver||Now||tbc|
|Florida||Moffat Tampa||Now||Dr Strosberg|
|Florida||Miami Cancer Center||Summer 2018||tbc|
|Georgia||Emory Atlanta||Estimated June 2018||tbc|
|Georgia||CCTA Newnan, Atlanta||Now||Dr. Phan|
|Illinois||Rush University Chicago||Now||Xavier M. Keutgen, MD|
|Illinois||The University of Chicago Medicine||now||tbc|
|Iowa||University of Iowa||now||Dr T O’Dorisio|
|Massachusetts||Dana Farber Boston||Now||tbc|
|Massachusetts||Massachusetts General Hospital||Now||tbc|
|Minnesota||Mayo Rochester||26 Apr 2018||Dr. Thor Halfdanarson|
|Minnesota||University of Minnesota Health||Now||tbc|
|Missouri||Sara Canon Cancer Center Kansas City||Now||tbc|
|Missouri||Siteman Cancer Center St. Louis||Now||tbc|
|Missouri||Barnes Jewish Hospital St. Louis||Now||tbc|
|Nebraska||CHI Bergan||Now||Dr Samuel Mehr|
|New York||Lenox Hill NYC||Now||tbc|
|New York||Roswell Park Buffalo||Now||Dr Iyer|
|New York||Mount Sinai||Now||tbc|
|New York||NYU Langone||Now||tbc|
|Ohio||The James, Columbus||Now||Dr Shah|
|Oregon||Kaiser Portland||Estimated Aug 2018||tbc|
|Pennsylvania||Fox Chase Philadelphia||Now||Dr Paul Engstrom|
|Tennessee||Vanderbilt Nashville||Apr 2018||tbc|
|Texas||MD Anderson Houston||Summer 2018||tbc|
|Texas||Excel Diagnostics Houston||Now||tbc|
|Texas||CHI St Lukes Houston||Now||tbc|
|Utah||Huntsman Cancer Institute, Salt Lake City||10 May||tbc|
|Virginia||Carilion Clinic Roanoke||now||tbc|
|Washington (State)||Virginia Mason Seattle||Now||Dr. Hagen Kennecke|
|Wisconsin||UW Health Madison, Carbone Cancer Center||Now||Noelle K. LoConte, MD Specialty: Medical Oncology Primary Location: UW Carbone Cancer Center (608) 265-1700 (800) 323-8942|
|Wisconsin||Froedtert Milwaukee||Now||Dr Thomas|
PRRT is only available at a few cancer centres in Canada. It can only be used with special approval from Health Canada or by taking part in a clinical trial
Europe (EU affiliated countries)
The European Medicines Agency (EMA) “market authorisation” received a positive indication on 20th July followed by EC approval on 29 Sep 2017. The positive indication reads “Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults”. Of Course, the decision to fund the drug will be with national approval organisations. Whilst I’m sure there are many more, these well-known centres have been making PRRT available for some years (but please note there are others):
Netherlands – Rotterdam Treatment Centre – click here
Sweden – Department of Endocrine Oncology Uppsala University Hospital – click here
Switzerland – University Hospital Basel, Radiology & Nuclear Medicine Clinic – click here
Germany – Zentralklinik Bade Berka – click here
Denmark – ‘Rigshospitalet’ since 2009. They have treated around 250 patients- and given 800 treatments.
UK – Royal Free Hospital – click here
I’d be interested to hear from countries in Europe with their full list of centres or a link to it.
Australia seems to be ahead of the game or that is what I sense when I read output from there. There’s a good section on the Australian effort – click here.
These guys have had to fight to get some progress on the provision of PRRT. Currently New Zealanders have to go to Melbourne Australia for treatment – almost 50 New Zealanders with NETs are currently raising tens of thousands of dollars to pay for treatment in Australia because the life-prolonging treatment isn’t available locally. But this could change in 2018. Unicorn Foundation New Zealand announced that Pharmac, the New Zealand government agency that decides which pharmaceuticals, have said that PRRT will be funded for patients with medium priority for the treatment of unresectable or metastatic, well-differentiated NETs (irrespective of primary site) that express somatostatin receptors.
- Pretoria – Steve Biko Academic Hospital and the University of Pretoria
- Johannesburg – The Wits Donald Gordon Hospital
- Durban – Umhlanga Molecular Imaging and Therapy Centre of Excellence at Umhlanga Hospital
- Cape Town – Tygerberg Hospital
Middle East, Asia and the Far East
Turkey – Istanbul, Dr.Levent Kabasakal.
Lebanon – The American Hospital of Beirut – Dr Ali Shamseddine “We have started using Lu-177 here in Lebanon. So far, we have treated 3 patients, with good response. The operational cost is much less than in Europe”.
|Ali Shamseddine, MD, CHB||Professor and Head of Divisionemail@example.com|
India – Mahatma Gandhi Cancer Hospital, Visakhapatnam. Recently started radionuclide therapy. Although only currently available privately, some patients have been sponsored by the companies that they work for. Point of contact is Dr. K. Raghava Kashyap. I’ve been assured by CNETS India that many locations have PRRT capability – contact them direct please.
Pakistan – check out this article – click here
Philippines – St. Luke’s Medical Center, Global City, Taguig, Metro Manila.
What’s next for NETs PRRT?
- two radiopeptides together;
- radiopeptides in conjunction with other chemotherapies (check out my article PRCRT);
- repeated administrations of the radiotherapies;
- other radionuclide-peptide combinations.
- increasing the number of indications for this therapy, including other disease targets;
- e.g. they are already using it for Prostate Cancer.
- e.g. new radionuclides – see my article about the COMPETE trial.
- See article “PRRT – The Sequel? – Targeted Alpha-emitter Therapy (TAT)”
See this great summary from NET Research Foundtion of what might be next plus basic facts about PRRT – click here
Thanks for reading
Please Share this post